Skip to main content
. 2019 Jun 14;49(10):1114–1120. doi: 10.1111/hepr.13362

Figure 1.

Figure 1

Sustained virologic response rate at 12 weeks after end of treatment (SVR12) with elbasvir/grazoprevir among 353 patients with hepatitis C virus (HCV) genotype 1, grouped by patient characteristics. Although age, sex, presence of cirrhosis, history of hepatocellular carcinoma (HCC), and renal disorder (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2) are not significantly associated with SVR, a history of interferon (IFN) therapy significantly decreases the SVR rate.